Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) just unveiled an announcement.
Fusen Pharmaceutical Co., Ltd. has issued a profit warning for the fiscal year ending December 31, 2024, anticipating a significant increase in losses compared to the previous year. The expected loss, ranging from RMB170 million to RMB210 million, is attributed to industry-wide inventory destocking, increased R&D expenses, and an impairment loss on an associate company. Despite these challenges, the company maintains a stable gross profit margin. Stakeholders are advised to exercise caution when dealing with the company’s securities.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on research and development, manufacturing, and sales of pharmaceutical products.
YTD Price Performance: -65.00%
Average Trading Volume: 442,833
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$227.9M
See more data about 1652 stock on TipRanks’ Stock Analysis page.